Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304200 · ClinicalTrials.gov registry record · Phase 1
Temodar and Sutent as Therapy for Melanoma
A Phase 1 study, sponsored by Northern California Melanoma Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00304200 is a Phase 1 study that was terminated before completion, run by Northern California Melanoma Center. The registered enrollment target is 7 participants.
The verdict
NCT00304200, a Phase 1 study, was terminated before completion, sponsored by Northern California Melanoma Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determine if there is clinical benefit as determined by the primary end-point of progression-free survival (PFS) at 6 months and additional secondary endpoints (Phase II).
Interventions
- DRUG Temozolomide and SU11248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304200
The ClinicalTrials.gov registry entry for NCT00304200 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern California Melanoma Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temozolomide and SU11248 is the first listed.
NCT00304200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00304200 about?
NCT00304200 is a clinical study titled "Temodar and Sutent as Therapy for Melanoma". This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determi...
What is the current status of trial NCT00304200?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2006-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00304200?
The interventions under investigation include: Temozolomide and SU11248 (DRUG).
Who is sponsoring clinical trial NCT00304200?
This trial is sponsored by Northern California Melanoma Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.